About this trial
this study aims to assess the short-term (3-month) clinical and echocardiographic outcomes of primary PCI among STEMI patients from rural versus urban areas in Upper Egypt. A special focus will be placed on identifying predictors of MACE. The findings may offer valuable insight into optimizing STEMI care pathways and support the development of regional STEMI networks across Egypt.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Adults aged ≥18 years. 2. Confirmed diagnosis of ST-segment elevation myocardial infarction (STEMI) based on ECG and cardiac biomarkers.
Disqualifiers
Non-STEMI or unstable angina cases.
Patients who received fibrinolytic therapy instead of PCI.
Transfer from another facility after more than 12 hours of symptom onset.
Patients with previous revascularization (e.g., CABG or PCI within the last 6 months).
Trial population
patients Confirmed diagnosis of ST-segment elevation myocardial infarction (STEMI) based on ECG and cardiac biomarkers.
Trial design
Cohort
Prospective
Treatments tested in this trial
Primary Percutaneous Coronary Intervention (PPCI)
DeviceA catheter-based invasive procedure used to open blocked coronary arteries in patients presenting with ST-elevation myocardial infarction (STEMI).
Treatment groups
Trial outcomes
Primary outcomes
Incidence of major adverse cardiovascular events (MACE) among STEMI patients undergoing primary percutaneous coronary intervention (PCI),
Unite of measurement : Number of patients experiencing MACE (% of total)
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: